Efficacy and Effect on Plasma B-type Natriuretic Peptide Concentration of Losartan-hydrochlorothiazide for Hypertension Uncontrolled by Losartan-based Therapy: Subanalysis of a Multicentre Prospective Observational Study

Abstract

Many patients with hypertension have difficulty achieving their target blood pressure (BP). Therefore combination therapy, for example with an angiotensin II receptor blocker (ARB) and a diuretic, may be recommended. We previously evaluated the efficacy and safety of losartan (LOS) 50 mg – hydrochlorothiazide (HCTZ) 12.5 mg, as well as its effect on the plasma concentration of B-type natriuretic peptide (BNP, a prognostic marker for cardiovascular events), in patients with hypertension uncontrolled by ≥3 months of ARB-based therapy. The present subanalysis used data from patients who received LOS-based therapy before switching to LOS–HCTZ. Efficacy, safety, and changes in blood biochemical variables including BNP were evaluated. After excluding 4 patients with protocol violations, data from 35 patients (aged 36–79 years, mean 63 years; 66% male) were used in the safety analysis. The efficacy analysis used data from the 30 patients who were followed up for 12 months. Systolic/diastolic BP decreased from 156±12/87±11 mmHg at baseline to 125±11/73±10 mmHg at 12 months (p<0.001). After 12 months, half of the patients achieved their target BP as defined by the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004. In 12 patients with baseline plasma BNP concentration ≥20 pg/mL, BNP decreased from 78.3±18.8 pg/mL to 57.3±17.7 pg/mL (p<0.01). 3 patients experienced adverse events, one of which was cardiovascular. LOS-HCTZ is efficacious, has a good safety profile, and decreases plasma BNP concentration.

Key words

angiotensin II receptor antagonist - losartan - hydrochlorothiazide - hypertension - B-type natriuretic peptide

• References

• 1 Jafar TH, Stark PC, Schmid CH et al. AIPRD Study Group . Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med Aug 2003; 139 (04) 244-252
• 2 Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J Hypertens Jun 1995; 13 (06) 571-579
• 3 Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol Apr 1996; 27 (05) 1214-1218
• 4 Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA Mar 1997; 277 (09) 739-745
• 5 Japanese Society of Hypertension . Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res Aug 2006; 29 (Suppl) S1-S105
• 6 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med Nov 1997; 157 (21) 2413-2446
• 7 Hozawa A, Ohkubo T, Kikuya M et al. Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res Jan 2002; 25 (01) 57-63
• 8 Heart Care Network Groups . Current trends in lifestyle-related disease management by general practitioners: a report from the ‘Heart Care Network’ groups. J Atheroscler Thromb 2009; 16 (06) 799-806
• 9 Murai K, Obara T, Ohkubo T et al. J-Home Study Group . Current usage of diuretics among hypertensive patients in Japan: the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res Nov 2006; 29 (11) 857-863
• 10 Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents – a preliminary report. Hypertension Feb 2007; 49 (02) 272-275
• 11 Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med Mar 2009; 122 (03) 290-300
• 12 Ogihara T, Kikuchi K, Matsuoka H et al. Japanese Society of Hypertension Committee . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res Jan 2009; 32 (01) 3-107
• 13 Mancia G, Laurent S, Agabiti-Rosei E et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens Nov 2009; 27 (11) 2121-2158
• 14 Julius S, Kjeldsen SE, Weber M et al.; VALUE trial group . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet Jun 2004; 363 (9426) 2022-2031
• 15 Hirata Y, Matsumoto A, Aoyagi T et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res Aug 2001; 51 (03) 585-591
• 16 Tsuchida K, Tanabe K. Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol Dec 2008; 52 (03) 212-223
• 17 Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med Feb 2004; 350 (07) 655-663
• 18 Suzuki M, Hamada M, Yamamoto K et al. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res Sep 2002; 25 (05) 669-676
• 19 Olsen MH, Wachtell K, Tuxen C et al. N-terminal pro–brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens Aug 2004; 22 (08) 1597-1604
• 20 Olsen MH, Wachtell K, Tuxen C et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens May 2005; 23 (05) 1083-1090
• 21 Meno H, Inou T, Tanaka M et al. Antihypertensive efficacy of the losartan/hydrochlorothiazide combination and its effect on plasma B-type natriuretic peptide in hypertensive patients uncontrolled by angiotensin II type 1 receptor antagonist–based therapy: a multicentre prospective observational study. Clin Drug Investig March 2012; 32 (03) 171-178
• 22 Higaki J. Survey on the current status of prescription of combination therapy with antihypertensive agents for hypertensive patients and opinion on a combination drug in Japan. Prog Med 2006; 26: 757-763 [In Japanese]
• 23 Shimada K, Yano Y. Treatment of hypertension in Japan after the introduction of angiotensin receptor antagonists. Biomed Ther 2006; 40: 5-9 [In Japanese]
• 24 Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension Dec 2003; 42 (06) 1206-1252
• 25 Griffing GT, Sindler BH, Aurecchia SA et al. The effects of hydrochlorothiazide on the renin–aldosterone system. Metabolism Feb 1983; 32 (02) 197-201
• 26 Ikeda LS, Harm SC, Arcuri KE et al. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press Jan 1997; 6 (01) 35-43
• 27 PROGRESS Collaborative Group . Randomised trial of a perindopril-based blood-pressure–lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet Sep 2001; 358 (9287) 1033-1041
• 28 Kato J, Eto T. Diuretics in the LIFE study. Lancet Jul–Aug 2004; 364 (9432) 413 author reply 413–414
• 29 Hirose H, Kawabe H, Saito I. Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects. Clin Exp Hypertens 2011; 33 (01) 41-46
• 30 Kim KS, Fan WH, Kim YD et al. Asia HEAALTH Study Investigators. Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy. Hypertens Res Jun 2009; 32 (06) 520-526
• 31 Kinouchi K, Ichihara A, Sakoda M et al. Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertens Res Dec 2009; 32 (12) 1143-1147
• 32 Shimosawa T, Gohchi K, Yatomi Y et al. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res Sep 2007; 30 (09) 831-837
• 33 Kita T, Yokota N, Ichiki Y et al. One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res Apr 2010; 33 (04) 320-325
• 34 Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med Aug 2007; 120 (08) 713-719
• 35 Soualmia H, Ayadi I, Omar S et al. Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension. Clin Lab 2009; 55 (3–4) 120-127
• 36 Kohno M, Horio T, Yokokawa K et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med Jan 1992; 92 (01) 29-34
• 37 Paget V, Legedz L, Gaudebout N et al. N-terminal pro–brain natriuretic peptide: a powerful predictor of mortality in hypertension. Hypertension Apr 2011; 57 (04) 702-709
• 38 Dahlöf B, Zanchetti A, Diez J et al. REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens Sep 2002; 20 (09) 1855-1864
• 39 Kawai T, Takei I, Shimada A et al. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study. Clin Drug Investig 2011; 31 (04) 237-245
• 40 Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature May 2002; 417 (6887) 447-452